Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   R ecurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma Interventions:   Drug: Copanlisib;   Drug: Niraparib Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials